Akompong T, VanWye J, Ghori N, Haldar K
Department of Microbiology and Immunology, Stanford University School of Medicine, CA 94305-5402, USA.
Mol Biochem Parasitol. 1999 Jun 25;101(1-2):71-9. doi: 10.1016/s0166-6851(99)00056-0.
There is great need to identify and characterize drug targets and chemotherapeutic strategies against malaria. Here we show that a vacuolar-network induced by the human malaria parasite Plasmodium falciparum, is a major import pathway for artemisinin, a leading, new anti-malarial that is known to be effective against drug resistant strains. We also show that artemisinin-treatment induces aberrant, budding of a vacuolar-network membrane protein and its antimalarial activity is additive with toxic sphingolipid analogues that block the network. The data suggest that artemisinin alters membrane protein export from the vacuolar-network and combinations with anti-network reagents have the potential to provide powerful new chemotherapy for drug resistant malaria.
迫切需要确定并描述针对疟疾的药物靶点和化疗策略。在此,我们表明,由人类疟原虫恶性疟原虫诱导形成的液泡网络,是青蒿素的主要导入途径,青蒿素是一种新型的主要抗疟药物,已知对耐药菌株有效。我们还表明,青蒿素处理会诱导液泡网络膜蛋白异常出芽,其抗疟活性与阻断该网络的有毒鞘脂类似物具有相加作用。这些数据表明,青蒿素改变了液泡网络的膜蛋白输出,与抗网络试剂联合使用有可能为耐药疟疾提供强大的新型化疗方法。